Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

COVID-19: Post-exposure prophylaxis with ivermectin in contacts. At Homes, Places of Work, Nursing Homes, Prisons, and Others

Chang et al., ResearchGate, doi:10.13140/RG.2.2.34561.48483/2
Jul 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
Proposed PEP protocol based on ivermectin.
Chang et al., 31 Jul 2020, preprint, 2 authors.
This PaperIvermectinAll
COVID-19: POST-EXPOSURE PROPHYLAXIS WITH IVERMECTIN IN CONTACTS. At Homes, Places of Work, Nursing Homes, Prisons, and Others
Gustavo Trujillo, Aurora Researchgate, July, Madeline Oh
Post-Exposure Prophylaxis (PEP) is aimed at preventing the development of infection and disease after exposure to an infectious agent. PEP is indicated by the WHO, PAHO, the United States HHS and other widely recognized organizations for HIV infection, as well as for other infectious diseases such as Hepatitis B and C, Tuberculosis and Scabies. In the case of COVID-19, PEP is indicated for Contacts of people with a diagnosis of SARS CoV-2 infection. The identification of the Contacts of the infected person is carried out mainly in his or her Place of Residence and Work. If applicable, it is also carried out in School, modes of Transportation as well as other places where the infected may have stayed. PEP is also recommended in the case of Contact with persons suspected of having COVID-19. The Place of Residence may be a place where many people live, such as Nursing Homes, Prisons, Long-Term Residential Centers, Hospitals, among others. In these places, it is often justifiable to carry out large-scale PEP, especially if there are several people already sick on site. Based on local experience and existing publications, a general PEP Scheme consisting of a dose of 0.2 mg per kilo of weight for 2 days is proposed. A third dose (3 days) is indicated in male Contacts between the ages of 45 and 70. And 4 doses is given for men older than 70, and in the person(s) who assume(n) the role of "Caregiver". The inclusion of Acetylsalicylic Acid (ASA) or Aspirin in the PEP Scheme is recommended in for men over 45 years of age and in "Persons with Increased Risk" of developing severe illness. Recommended dose is 1 tablet of 100 mg after lunch for 6 to 10 days. Contacts should remain under observation in case they begin to show characteristic symptoms of COVID-19, in which case they should move to therapeutic doses of Ivermectin. Special care must be taken in elderly people who are bedridden or with reduced mobility, in whom health checks must be more frequent and comprehensive.
Aguirre-Chang, Trujillo, COVID-19: Profilaxis Post-Exposición con Ivermectina en Contactos adultos y adultos mayores
Beeres, Ravensbergen, Heidema, Efficacy of ivermectin mass-drug administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 -March 2016, PLoS Negl Trop Dis, doi:10.1371/journal.pntd.0006401
Bienvenu, Marty, Jones, Picot, Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020, One Health
Blanc, Lordkipanidzé, Platelet Function in Aging, Front Cardiovasc Med, doi:10.3389/fcvm.2019.00109
Boulware, Pullen, Bangdiwala, A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Chee Seong, A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of Covid-19 (DORM Trial
Colmenero, Santonja, SARS CoV-2 endothelial infection causes COVID?19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases, Br J Dermatol, doi:10.1111/bjd.19327
Fde, Taciro, Guerra, Eckley, Oral ivermectin for the treatment and prophylaxis of scabies in prison, J Dermatolog Treat, doi:10.1080/09546630510041277
Galvis, Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials, Ach Bronco
Giannessi, Aiello, Franchi, Percario, Affabris, The role of extracellular vesicles as allies of HIV, HCV and SARS viruses, Viruses, doi:10.3390/v12050571
Gu, Dayal, Inflammation mediated platelet hyperactivity in aging, Ann Blood, doi:10.21037/aob.2020.03.01
Inal, COVID-19 comorbidities, associated procoagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity?, British Journal of Haematology, doi:10.1111/bjh.17011
Iyer, Dayal, Modulators of platelet function in aging, Platelets, doi:10.1080/09537104.2019.1665641
Lee, Son, Peck, Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?, Int J Antimicrob Agents
Ops, Vih, /SIDA. Profilaxis Posterior a la Exposición (PEP)
Romani, Whitfeld, Koroivueta, Mass Drug Administration for Scabies Control in a Population with Endemic Disease, N Engl J Med, doi:10.1056/NEJMoa1500987
Shouman, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19
Varga, Endothelial cell infection and endotheliitis in COVID-19, The Lancet, doi:10.1016/S0140-6736(20)30937-5
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop